Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

Rhythm · Phase 3 · Completed · Enrollment 52

NCT03746522

EudraCT 2018-004058-11

ArmPopulationDoseWeeksEstimandWeight change
Setmelanotide (Double-Blind)Bardet Biedl Syndrome (BBS); Alström Syndrome...n/r52n/rn/r
Placebo (Double-Blind)Bardet Biedl Syndrome (BBS); Alström Syndrome...n/r52n/rn/r
Setmelanotide (Open-label)Bardet Biedl Syndrome (BBS); Alström Syndrome...n/r52n/rn/r
Pivotal CohortBardet Biedl Syndrome (BBS); Alström Syndrome...n/r52n/r-5.21% at week 52